JCEM:SH和DKA在SES较低的患者中更常见

2013-06-17 JCEM dxy

很少有研究评估成年人1型糖尿病重度低血糖(SH)和糖尿病酮症酸中毒(DKA)的相关因素。为了确定成年人1型糖尿病重度低血糖和糖尿病酮症酸中毒发生的频率和相关因素,来自美国芭芭拉·戴维斯儿童糖尿病中心Kellee M Miller教授及其团队进行了一项研究,该研究发现在较低社会经济地位(SES)的患者中,重度低血糖和糖尿病酮症酸中毒更常见。该研究结果在线发表在2013年6月12日的《临床内分泌代谢杂

很少有研究评估成年人1型糖尿病重度低血糖(SH)和糖尿病酮症酸中毒(DKA)的相关因素。为了确定成年人1型糖尿病重度低血糖和糖尿病酮症酸中毒发生的频率和相关因素,来自美国芭芭拉·戴维斯儿童糖尿病中心Kellee M Miller教授及其团队进行了一项研究,该研究发现在较低社会经济地位(SES)的患者中,重度低血糖和糖尿病酮症酸中毒更常见。该研究结果在线发表在2013年6月12日的《临床内分泌代谢杂志》(The journal of clinical endocrinology & metabolism)上。

该研究是对来自1型糖尿病交流中心临床登记的横断面分析,包括70家美国内分泌中心。分析包括7012例在1型糖尿病交流中心临床登记、年龄26-93岁、1型糖尿病病程≥2年的受试者。

该研究结果表明,较高频率的重度低血糖和糖尿病酮症酸中毒与较低的社会经济地位(SES)有关(p<0.001)。重度低血糖与糖尿病病程密切相关(p<0.001),糖尿病病程大于≥40年的患者中,18.6%在过去12个月期间有重度低血糖发生。HbA1c水平在7.0%(53mmol/mol)至7.5%(58mmol/mol)的患者中,重度低血糖的频率最低,而在HbA1c水平<7.0%(<53mmol/mol)或HbA1c水平>7.5%(>58mmol/mol)的患者中,重度低血糖的频率增加。在较高HbA1c水平的患者中,糖尿病酮症酸中毒的发生频率增加(p<0.001),HbA1c≥10.0%的患者中,21.0%在过去12个月期间有酮症酸中毒发生。

该研究发现,在较低社会经济地位(SES)的患者中,重度低血糖和糖尿病酮症酸中毒更常见。糖尿病酮症酸中毒在HbA1c≥10.0%的患者中最常见,应该在很大程度上是可以预防的。相反,重度低血糖在糖尿病病程≥40年的患者最常见,由于当前治疗的限制,这不能被消除。在糖尿病病程长的成年人,为了减少重度低血糖的发生,应当考虑改变HbA1c控制目标,特别是在那些HbA1c水平非常低的患者。

Severe Hypoglycemia and Diabetic Ketoacidosis in Adults with Type 1 Diabetes: Results from the T1D Exchange Clinic Registry.
Context
Few studies have assessed factors associated with severe hypoglycemia (SH) and diabetic ketoacidosis (DKA) in adults with type 1 diabetes (T1D).
Objective
Determine frequency of and factors associated with the occurrence of severe hypoglycemia (SH) and diabetic ketoacidosis (DKA) in adults with type 1 diabetes.
Design
Cross-sectional analysis from the T1D Exchange clinic registry.
Setting
70 U.S. endocrinology centers
Patients
Analysis included 7,012 participants in the T1D Exchange clinic registry aged 26-93 years old with T1D for ≥ 2 years.
Results
Higher frequencies of SH and DKA were associated with lower socio-economic status (SES) (p<0.001). SH was strongly associated with diabetes duration (p<0.001), with 18.6% of those with diabetes ≥40 years having an event in the past 12 months. SH frequency was lowest in those with HbA1c levels of 7.0% (53 mmol/mol) to 7.5% (58 mmol/mol), being higher in those with HbA1c levels <7.0% (<53 mmol/mol) or >7.5% (>58 mmol/mol). DKA frequency increased with higher HbA1c levels (p<0.001), with 21.0% of those with HbA1c ≥10.0% (≥86 mmol/mol) having an event in the past 12 months.
Conclusions
SH and DKA are more common in those with lower SES. DKA, most common in those with HbA1c ≥10.0% (≥86 mmol/mol), should be largely preventable. In contrast, SH, most frequent with diabetes ≥40 years duration, cannot be abolished given the limitation of current therapies. To reduce SH in adults with longstanding diabetes, consideration should be given to modifying HbA1c goals, particularly in patients with very low HbA1c levels.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2062814, encodeId=c02620628141b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Aug 21 04:35:00 CST 2013, time=2013-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777435, encodeId=a4f11e7743556, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Thu Nov 21 01:35:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469048, encodeId=35451469048f4, content=<a href='/topic/show?id=399d6018c6' target=_blank style='color:#2F92EE;'>#DKA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6018, encryptionId=399d6018c6, topicName=DKA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15e77003563, createdName=360611842, createdTime=Wed Jun 19 01:35:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569685, encodeId=455f15696858e, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Wed Jun 19 01:35:00 CST 2013, time=2013-06-19, status=1, ipAttribution=)]
    2013-08-21 achengzhao
  2. [GetPortalCommentsPageByObjectIdResponse(id=2062814, encodeId=c02620628141b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Aug 21 04:35:00 CST 2013, time=2013-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777435, encodeId=a4f11e7743556, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Thu Nov 21 01:35:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469048, encodeId=35451469048f4, content=<a href='/topic/show?id=399d6018c6' target=_blank style='color:#2F92EE;'>#DKA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6018, encryptionId=399d6018c6, topicName=DKA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15e77003563, createdName=360611842, createdTime=Wed Jun 19 01:35:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569685, encodeId=455f15696858e, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Wed Jun 19 01:35:00 CST 2013, time=2013-06-19, status=1, ipAttribution=)]
    2013-11-21 smallant2015
  3. [GetPortalCommentsPageByObjectIdResponse(id=2062814, encodeId=c02620628141b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Aug 21 04:35:00 CST 2013, time=2013-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777435, encodeId=a4f11e7743556, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Thu Nov 21 01:35:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469048, encodeId=35451469048f4, content=<a href='/topic/show?id=399d6018c6' target=_blank style='color:#2F92EE;'>#DKA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6018, encryptionId=399d6018c6, topicName=DKA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15e77003563, createdName=360611842, createdTime=Wed Jun 19 01:35:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569685, encodeId=455f15696858e, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Wed Jun 19 01:35:00 CST 2013, time=2013-06-19, status=1, ipAttribution=)]
    2013-06-19 360611842
  4. [GetPortalCommentsPageByObjectIdResponse(id=2062814, encodeId=c02620628141b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Aug 21 04:35:00 CST 2013, time=2013-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777435, encodeId=a4f11e7743556, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Thu Nov 21 01:35:00 CST 2013, time=2013-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469048, encodeId=35451469048f4, content=<a href='/topic/show?id=399d6018c6' target=_blank style='color:#2F92EE;'>#DKA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6018, encryptionId=399d6018c6, topicName=DKA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15e77003563, createdName=360611842, createdTime=Wed Jun 19 01:35:00 CST 2013, time=2013-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569685, encodeId=455f15696858e, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Wed Jun 19 01:35:00 CST 2013, time=2013-06-19, status=1, ipAttribution=)]
    2013-06-19 dongjia2015

相关资讯

BMJ:GLP-1类药物的安全性受到质疑

新型的糖尿病药物,像GLP-1类药物,被称为“糖尿病治疗的宠儿”–带给制药工业数十亿的收入。但是,这类药物是否与癌症风险增加有关,以及关于这些新治疗方案,我们是否完全了解? 英国医学杂志(BMJ)和第四频道发起了一项调查研究,发现在行业研究中提示这类药物具有潜在危害的证据没有被公开。一些独立研究的结果对药品生产厂家的结论提出质疑。目前一些医学专家和患者团体要求制药公司报告的研究数据更加透明,并参

JAMA:胃分流术可帮助控制糖尿病风险因子

据6月5日发表在《美国医学会杂志》上的一则研究披露,对于罹患II型糖尿病且具有轻度与中度肥胖的病人,将胃分流术加到生活方式及内科方法处理之中更有可能使诸如血糖、低密度脂蛋白-胆固醇及收缩压等代谢性风险因子的水平得到改善。 根据文章的背景资料:“II型糖尿病的治疗基础是减肥,减肥可以通过生活方式的改变来减少能量的摄入及增加身体的活动来达到。来自Look AHEAD (AHEAD :糖尿病的健康行动

Diabetes Care:糖尿病合并COPD患者应谨慎使用皮质激素类药物

经不同剂量皮质激素分层,因糖尿病并发症住院累积发生率 为了确定采用皮质激素治疗的糖尿病合并慢性阻塞性肺病(COPD)患者糖尿病并发症风险是否呈剂量依赖性增加。来自南澳大利亚大学药学和医学科学院药品使用质量和药学研究中心的Gillian E. Caughey博士等人进行了一项研究,研究发现,糖尿病合并COPD患者使用高剂量皮质激素时糖尿病相关住院风险明显增高。研究结果在线发表于2013年6月4日美

JAMA Intern Med:在老年糖尿病患者中 低血糖-痴呆症互为因果

  美国一项研究表明,在老年糖尿病(DM)患者中,低血糖和痴呆症之间可能存在双向相关性。论文6月10日在线发表于《美国医学会杂志·内科学》(JAMAInternMed)。   该前瞻性研究纳入783例老年DM患者(平均74.0岁;47.0%为黑人;47.6%为女性),其均参与了始于1997年、基于人群的“健康、老龄化和身体成分研究”,基线时改良的简易精神状态检查评分≥80

Diabetes :研究在骨髓中再造胰腺功能

一个意大利研究团队日前宣布,他们尝试在骨髓中部分再造胰腺功能获得成功,这将有助于糖尿病患者在胰腺切除手术后提高生活质量、降低并发症风险。最新出版的学术期刊《糖尿病》刊登了这一发现。 米兰圣拉斐尔医院的这个研究团队修改了针对1型糖尿病患者的胰岛移植程序。他们从捐赠者的胰腺中提取内分泌细胞,植入患者的盆骨骨髓中,“再造”部分胰腺功能。目前,研究团队已经在4位胰腺全部切除的糖尿病患者身上进行了临床试验

JCEM:SHG后代代谢性疾病发生风险增加

在妊娠期间妊娠剧吐改变母体(也可能包括胎儿)的营养状况,但目前缺乏妊娠剧吐对后代代谢长期影响的数据。为了评估严重妊娠剧吐(SHG)是否影响后代童年期间葡萄糖稳态和身体组成。来自新西兰奥克兰大学Liggins Institute教授及其团队进行了一项研究,该研究发现经历严重妊娠剧吐的母亲生出的胎儿有较低的胰岛素敏感性,可能增加他们向糖尿病发展的长期风险。该研究结果在线发表在2013年6月7日的《临床